The first-generation drug-eluting stents and coronary endothelial dysfunction.

Recently, a growing body of clinical data has shown that the first generation of drug-eluting stents (1st-gen DES) implantation could elicit coronary conduit artery vasomotor dysfunction at nonstented reference segments as late as 12 months after implantation compared with that seen with bare-metal stents. The mechanism of this phenomenon is still not fully understood. Pathological studies have implicated delayed arterial healing and poor re-endothelialization after the 1st-gen DES implantation. Given the vast use of DES globally, a thorough understanding of the early and long-term safety of these devices is paramount. Therefore, this article systematically reviews the current clinical, pathophysiological, and histopathological available data regarding 1st-gen DES-associated vascular endothelial dysfunction. Meanwhile, we will also review the newer generation of DES and emerging endothelial-friendly technology.

[1]  Timothy O'Brien,et al.  Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Gang-yi Wu,et al.  Removal of Fkbp12/12.6 From Endothelial Ryanodine Receptors Leads to an Intracellular Calcium Leak and Endothelial Dysfunction , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[3]  Mair Zamir,et al.  Functional anatomy and hemodynamic characteristics of vasa vasorum in the walls of porcine coronary arteries. , 2003, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.

[4]  J. Vane,et al.  Regulatory functions of the vascular endothelium. , 1990, The New England journal of medicine.

[5]  S. Moncada,et al.  The L-arginine-nitric oxide pathway. , 1993, The New England journal of medicine.

[6]  Dong Bin Kim,et al.  Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. , 2007, International heart journal.

[7]  K. Maekawa,et al.  Severe Endothelial Dysfunction After Sirolimus-Eluting Stent Implantation , 2006 .

[8]  W. Hillegass,et al.  Severe, diffuse coronary artery spasm after drug-eluting stent placement. , 2006, The Journal of invasive cardiology.

[9]  Antonio Colombo,et al.  Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in Humans , 2002, Circulation.

[10]  J. Kasprzak,et al.  Clinical aspects of assessment of endothelial function. , 2006, Pharmacological reports : PR.

[11]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[12]  P. Vanhoutte.  Other endothelium-derived vasoactive factors , 1993 .

[13]  K. Robinson,et al.  Abnormal vasomotor function of porcine coronary arteries distal to sirolimus-eluting stents. , 2008, JACC. Cardiovascular interventions.

[14]  O. Muller,et al.  Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses , 2008, Circulation. Cardiovascular interventions.

[15]  G. Stone,et al.  Clinical ResearchInterventional CardiologyIncidence, Timing, and Correlates of Stent Thrombosis With the Polymeric Paclitaxel Drug-Eluting Stent: A TAXUS II, IV, V, and VI Meta-Analysis of 3,445 Patients Followed for Up to 3 Years , 2007 .

[16]  S. Higano,et al.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.

[17]  K. Robinson,et al.  Endothelium-dependent vasomotor dysfunction in pig coronary arteries with Paclitaxel-eluting stents is associated with inflammation and oxidative stress. , 2009, JACC. Cardiovascular interventions.

[18]  P. Vanhoutte.  Endothelial control of vasomotor function: from health to coronary disease. , 2003, Circulation journal : official journal of the Japanese Circulation Society.

[19]  G. Bakris,et al.  Controlled-release carvedilol in the treatment of essential hypertension. , 2006, The American journal of cardiology.

[20]  R. Nagai,et al.  Potent Inhibitory Effect of Sirolimus on Circulating Vascular Progenitor Cells , 2005, Circulation.

[21]  K. Seung,et al.  Long-term coronary endothelial function after zotarolimus-eluting stent implantation. A 9 month comparison between zotarolimus-eluting and sirolimus-eluting stents. , 2008, International heart journal.

[22]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[23]  R. Henning,et al.  Rescue of arterial function by angiotensin-(1-7): towards improvement of endothelial function by drug-eluting stents , 2008, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[24]  Johan Lindbäck,et al.  Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.

[25]  Jin Won Kim,et al.  Delayed severe multivessel spasm and aborted sudden death after Taxus stent implantation , 2005, Heart.

[26]  K. Robinson,et al.  Low-dose paclitaxel elution by novel bioerodible sol-gel coating on stents inhibits neointima with low toxicity in porcine coronary arteries. , 2009, International journal of cardiology.

[27]  L. Räber,et al.  Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. , 2007, International journal of cardiology.

[28]  I. Meredith,et al.  The assessment of endothelial function in humans , 2001, Coronary artery disease.

[29]  D. Davis,et al.  Comparison of vasa vasorum after intravascular stent placement with sirolimis drug‐eluting and bare metal stents , 2008, Journal of medical imaging and radiation oncology.

[30]  A. Küttner,et al.  Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. , 1997, Circulation.

[31]  P. MacCarthy,et al.  Life-threatening coronary artery spasm following sirolimus-eluting stent deployment. , 2006, Journal of the American College of Cardiology.

[32]  M. Noshiro,et al.  OE-277 DEC1, a Member of the Fifth Clock-Gene Family, is Induced by Angiotensin II, Growth Factors, and Hypoxia in Vascular Cells(Hypertension, basic-1, The 71st Annual Scientific Meeting of the Japanese Circulation Society) , 2007 .

[33]  Amir Lerman,et al.  Endothelial Dysfunction: A Marker of Atherosclerotic Risk , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[34]  K. Kodama,et al.  Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study. , 2009, JACC. Cardiovascular imaging.

[35]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[36]  J. Pouysségur,et al.  p70 S6 Kinase-mediated Protein Synthesis Is a Critical Step for Vascular Endothelial Cell Proliferation* , 1999, The Journal of Biological Chemistry.

[37]  E. Kim,et al.  A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction. , 2009, Journal of the American College of Cardiology.

[38]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[39]  L. Lerman,et al.  The Interaction Between Coronary Endothelial Dysfunction, Local Oxidative Stress, and Endogenous Nitric Oxide in Humans , 2008, Hypertension.

[40]  Y. Saitoh,et al.  Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. , 2007, Journal of the American College of Cardiology.

[41]  Renu Virmani,et al.  One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. , 2009, JACC. Cardiovascular imaging.

[42]  I. Barasoain,et al.  Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. , 2003, Current cancer drug targets.

[43]  A. Kaltoft,et al.  Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. , 2007, Journal of the American College of Cardiology.

[44]  R. Virmani,et al.  Endothelial cell recovery between comparator polymer-based drug-eluting stents. , 2008, Journal of the American College of Cardiology.

[45]  I. Miyamori,et al.  Mechanisms of FK 506-induced hypertension in the rat. , 1999, Hypertension.

[46]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[47]  Peter Libby,et al.  Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.

[48]  Anthony A Bavry,et al.  Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. , 2006, The American journal of medicine.

[49]  E. Kim,et al.  Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus Paclitaxel-eluting stent. , 2008, JACC. Cardiovascular interventions.

[50]  W. Wijns,et al.  Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. , 2008, Journal of the American College of Cardiology.

[51]  K. Robinson,et al.  Drug-eluting stents: present and future. , 2008, Cardiovascular & hematological agents in medicinal chemistry.

[52]  P. Serruys,et al.  Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. , 2006, European heart journal.

[53]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[54]  D. Tüller,et al.  Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[55]  M. Carrier,et al.  Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[56]  G. Papandreou,et al.  Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent , 2002, Coronary artery disease.

[57]  O. Hess,et al.  Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. , 2005, Journal of the American College of Cardiology.

[58]  T. Münzel,et al.  Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. , 2008, Journal of the American College of Cardiology.

[59]  R. Virmani,et al.  Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.

[60]  K. Maekawa,et al.  Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[61]  S. Marx,et al.  Bench to bedside: the development of rapamycin and its application to stent restenosis. , 2001, Circulation.

[62]  P. Vanhoutte,et al.  Endothelium‐derived relaxing and contracting factors , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[64]  A M Zeiher,et al.  Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.

[65]  Michael Joner,et al.  Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing , 2007, Arteriosclerosis, thrombosis, and vascular biology.